http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101089198-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-728 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-04 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-728 |
filingDate | 2004-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2011-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2011-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-101089198-B1 |
titleOfInvention | Ophthalmic pharmaceutical composition containing acetylated hyaluronic acid |
abstract | Disclosure of Invention An object of the present invention is to provide an ophthalmic pharmaceutical composition for dry eyes that exerts a repair effect that remains on the cornea for a longer time. Specifically, an ophthalmic pharmaceutical composition containing acetylated hyaluronic acid and a pharmaceutically acceptable carrier is provided. Preferably, the average molecular weight of the acetylated hyaluronic acid is 10,000 to 1,000,000, and the number of acetyl group substitutions is 2.0 to 4.0. In a suitable form, the ophthalmic pharmaceutical composition is used for the treatment or prevention of dry eye, and in a more suitable form it is an eye drop for dry eye. |
priorityDate | 2003-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.